Inclusion Criteria:

- Patient has histologically proven stage IIIB with pleural effusion, stage IV or
recurrent non-squamous NSCLC.

- Patient has a Karnofsky performance status >=70%.

- Patient has adequate bone marrow function: WBC >= 3,000 cells/mm3, ANC >= 1,500
cells/mm3, platelet count >= 100,000 cells/mm3, Hgb >= 9.0 g/dL.

- Patient has adequate liver function: total bilirubin level <= 2.0 mg/dL, albumin >=
2.5 g/dL.

- Transaminases (aspartate aminotransferase (AST or SGOT) and/or alanine
aminotransferase (ALT or SGPT)) and alkaline phosphatase may be up to 2.5 x ULN.

- Patient has adequate renal function: a serum creatinine < 2 mg/dl

- Patient has signed a written informed consent.

- Patient has received at least one prior chemotherapeutic regimen for recurrent or
metastatic disease.

Exclusion Criteria:

- Patient has not received prior chemotherapeutic regimens for advanced disease.

- Patient has received prior biologic therapy targeting epidermal growth factor
receptor (EGFR) and/or Vascular endothelial growth factor (VEGF).

- Patient has received radiation therapy within the past 3 weeks.

- Patient has signs or symptoms of acute infection requiring systemic therapy.

- Patient exhibits confusion, disorientation, or has a history of major psychiatric
illness that may impair patient's understanding of the informed consent.

- Patient requires total parenteral nutrition with lipids.

- Patient has a history of uncontrolled heart disease and/or uncontrolled hypertension
(> 150/100 mmHg).

- Because of the possible teratogenic effect, pregnant women and women who are
currently breast-feeding may not participate in this study. - All women of
childbearing potential must have a negative pregnancy test within 24 hours prior to
enrolling in the study.

- Serious infection or other intercurrent illness requiring immediate therapy.

- Clinical/imaging evidence of Central Nervous System (CNS) malignancy or with recently
treated CNS malignancy, as well as those experiencing recent cerebrovascular accident
(CVA), or other CNS bleeding.

- Pediatric patients in whom open growth plates would be expected.

- Urine protein qualitative value of > 30 in urinalysis or > +1 in proteinuria testing
by dipstick.

- Patient has a clinical history of coagulopathy or thrombosis.

- Patient is currently receiving or intending to receive anti-coagulants.

- Patient has had a recent myocardial infarction (still inside the healing period).
Note: a six-month window is optimal.

- Patient is recovering from recent major surgery (e.g., less than 2 weeks since
surgery) or is anticipating major surgery.

- Patient has a clinical history of hemoptysis or hematemesis.

- Patient may not have percutaneous endoscopic gastrostomy (PEG) or gastrostomy (G)
tube.